Find a Drug
Advanced Search

Professional

Benefix

Side Effects & Drug Interactions
font size

SIDE EFFECTS

See also CLINICAL PHARMACOLOGY: Clinical Studies.

As with the intravenous administration of any protein product, the following reactions may be observed after administration: headache, fever, chills, flushing, nausea, vomiting, lethargy, or manifestations of allergic reactions. Should evidence of an acute hypersensitivity reaction be observed, the infusion should be stopped promptly and appropriate counter measures and supportive therapy should be administered.

During uncontrolled open-label clinical studies with BeneFIX ® , Coagulation Factor IX (Recombinant), conducted in previously treated patients (PTPs), 131 adverse reactions with definite, probable, possible or unknown relation to BeneFIX ® therapy were reported among 27 of 65 subjects (with some subjects reporting more than one event) who received a total of 7573 infusions. These adverse reactions are summarized in Table 1 below.

Table 1:    Adverse Events Reported for PTPs *
Reaction
Total number of events
with definite, probable, possible or unknown
relation to therapy
(n=129) 		Number and (%) of
patients from which the
reports originated
(n=65) 		Number and (%) of
infusions temporally
associated with the
reaction 1
(n=7573)
Nausea
27 4 (6.2 %) 27 (0.36 %)
Taste perversion
(Altered taste)
14 3 (4.6 %) 19 (0.25 %)
Hypoxia
(Urge to cough with  hypoxemia)
11 1 (1.5 %) 11 (0.15 %)
Injection site reaction
11 5 (7.7 %) 12 (0.16 %)
Injection site pain
10 4 (6.2 %) 16 (0.21 %)
Headache
10 7 (10.8 %) 13 (0.17 %)
7 5 (7.7 %)  8 (0.11 %)
7 3 (4.6 %)  9 (0.12 %)
Pain (Burning sensation in the
  jaw and skull)
6 1 (1.5 %)  7 (0.09 %)
6 5 (7.7 %)  7 (0.09 %)
3 2 (3.1 %)  3 (0.04 %)
Flushing
3 2 (3.1 %)  4 (0.05 %)
Fever
2 2 (3.1 %)  2 (0.03 %)
Shaking
2 2 (3.1 %)  1 (0.01 %)
Factor IX inhibitor 2
1 1 (1.5 %)  2 (0.03 %)
Chest tightness
1 1 (1.5 %)  4 (0.05 %)
Drowsiness
1 1 (1.5 %)  1 (0.01 %)
Visual disturbance
1 1 (1.5 %)  1 (0.01 %)
Cellulitis at the IV site
1 1 (1.5 %)  7 (0.09 %)
Phlebitis at the IV site
1 1 (1.5 %)  7 (0.09 %)
Dry cough
1 1 (1.5 %)  0 (0.00 %)
1 1 (1.5 %)  1 (0.01 %)
1 1 (1.5 %)  1 (0.01 %)
Lung disorder
1 1 (1.5 %)  1 (0.01 %)
Vomiting
1 1 (1.5 %)  1 (0.01 %)
1 1 (1.5 %)  1 (0.01 %)
Total
131 27/65 (41.5 %) 148/7573 (2.2 %)
*More than one event in the table could have been assoc. with an infusion; however, the total represents the actual number of infusions given.
1 Reaction occurring within 72 hours after infusion.
2 Low titer transient inhibitor formation.
3 The renal infarct developed in a hepatitis C antibody positive patient 12 days after a dose of BeneFIX® for a bleeding episode. The relationship of the infarct to the prior administration of BeneFIX ® is uncertain. (See PRECAUTIONS, General).

One subject discontinued BeneFIX. due to pulmonary allergic-type symptoms.

In the 63 treated PUPS, who received a total of 5538 infusions, 22 adverse reactions were reported as having definite, probable, possible or unknown relationship to BeneFIX®. These events are summarized in Table 2 below.

Table 2: Adverse Events reported for PUPs *
Reaction
Total number of events
with definite, probable, possible or unknown
relation to therapy
(n=22) 		Number and (%) of
patients from which the
reports originated
(n=63) 		Number and (%) of
infusions temporally
associated with the
reaction 1
(n=5538)
Diarrhea
5 1 (1.6 %) 11 (0.20 %)
Urticaria (hives)
3 3 (4.8 %) 3 (0.05 %)
Factor IX inhibitor 2
2 2 (3.2 %) 4 (0.07 %)
Dyspnea (Respiratory distress)
2 2 (3.2 %) 2 (0.04 %)
1 1 (1.6 %) 3 (0.05 %)
Elevated ALT
1 1 (1.6 %) 0 (0.00 %)
Rash (Body rash)
1 1 (1.6 %) 1 (0.02 %)
Elevated AST
1 1 (1.6 %) 0 (0.00 %)
Chills (Rigors)
1 1 (1.6 %) 3 (0.05 %)
Photosensitivity reaction
1 1 (1.6 %) 0 (0.00 %)
Injection site reaction
1 1 (1.6 %) 2 (0.04 %)
1 1 (1.6 %) 2 (0.04 %)
Parvovirus B19 seroconversion 4
1 1 (1.6 %) 1 (0.02 %)
1 1 (1.6 %) 1 (0.02 %)
Total
22 11/63 (17.5%) 27/5538 (0.60%)
*More than one event in the table could have been assoc. with an infusion; however, the total represents the actual number of infusions given.
1 Reaction occurring within 72 hours after infusion.
2 Two subjects developed high titer inhibitor formation during treatment with BeneFIX®.
3 Relationship of HAV seroconversion to BeneFIX® is unknown. HAV seroconversion was noted on 2 occasions in a single patient but was negative at final visit. The patient had no laboratory or clinical findings associated with active infection.
4 Relationship of Parvovirus B19 seroconversion to BeneFIX ® is unknown. It was unlikely that seroconversion was related to BeneFIX® due to the frequency of community acquired infection and viral safeguards built into the manufacturing process (See DESCRIPTION ).

The following post-marketing adverse reactions have been reported for BeneFIX®, as well as for plasma-derived factor IX products: inadequate factor IX recovery, inadequate therapeutic response, inhibitor development (see CLINICAL PHARMACOLOGY ), anaphylaxis (see WARNINGS), laryngeal edema, angioedema, cyanosis, dyspnea, hypotension, thrombosis.

If any adverse reaction takes place that is thought to be related to the administration of BeneFIX® the rate of infusion should be decreased or the infusion stopped.

 

DRUG INTERACTIONS

No Information Provided.

Brand Name: Benefix
Generic Name: Coagulation Factor IX Recombinant

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Bookmark this page:


Privacy Policy

Women's Health

Find out what women really need.

WebMD Symptom Checker - Start Here Ringworm Slideshow: Watch and Learn

Herbal First AidHerbal First Aid
Herbal medicine is ancient, but only in recent years have many people started to take notice of its all natural healing powers. See more WebMD Videos »